Metabolite Monitoring for Diabetes in High-Risk Populations

Votes: 0
Views: 489
Medical

Some 1 in 3 Americans have pre-diabetes, yet the vast majority (80%) don’t know it. Blood tests are performed too late, require specialist staff, and performed only by healthcare providers. The cost of allowing pre-diabetes to go undetected is that $1 of every $4 in US healthcare costs is spent on diabetes care.

ViBo Health is tackling the challenge of accurately tracking health conditions, wellness, fitness, nutrition, and recovery. Our product, DigiScan™, exploits advances in clinically proven diagnostic healthcare technologies. We are democratizing technology developed over many decades for Magnetic Resonance Imaging (MRI) and its sister technology, Magnetic Resonance Spectroscopy (MRS).

MRS is widely used as a tool for metabolomic research and can identify the biochemical composition of targeted volumes of tissue without contact or pain. However, current MRS technology is only available on expensive, large, high-end machines, and is usually limited to specialized clinical and research settings. There is no point-of-care device which provides accessible, low-cost, non-specialist, and long-term metabolic tracking.

DigiScan™ will miniaturize MRS within a small, desktop device to automatically check biochemistry from a finger. The device combines multiple developments in MRS with advanced signal processing to maximize measurement quality. By accurately detecting multiple biomarkers (metabolites), DigiScan™ can assess underlying health states and detect early signs of disease, such as pre-diabetes.

The value of the technology is to: 1) Reduce negative health consequences for individuals; 2) Provide a simple and noninvasive way for individuals to monitor their health over time; and 3) Save healthcare systems and companies the colossal cost of treating chronic conditions by identifying the pre-patient.

With a 10-second finger scan, DigiScan™, will inform individuals of their pre-diabetic status based on the detection of relevant biomarkers: our goal is to identify in-vitro at least 3 metabolites validated for the identification of pre-diabetes from glucose variability, insulin, A1C, lipid changes, lactate, etc.

We make it easy to get health and stay healthy.

Video

Like this entry?

Voting is closed!

  • About the Entrant

  • Name:
    Gil Travish
  • Type of entry:
    team
    Team members:
    • Ron Stone
  • Software used for this entry:
    We have used a mix of tools from COMSOL to SolidWorks to specialized NMR software
  • Patent status:
    pending